Exhibit 10.1
AMENDED AND RESTATED LICENSE AGREEMENT
     This Amended and Restated License Agreement (the “Agreement”) is entered
into as of August 19, 2011 (the “Restatement Date”), by and between Universal
Biosensors Pty Ltd, ACN 098 234 309, a company incorporated in Victoria,
Australia, of 1 Corporate Avenue, Rowville, Victoria 3178, Australia (“UBS”),
and LifeScan, Inc., a California corporation having its principal place of
business at 1000 Gibraltar Drive, Milpitas, California 95035 (“LifeScan”).
     Whereas, Universal Biosensors, Inc., a Delaware corporation and UBS’s
parent company (“UBI” and, collectively with UBS, “Universal Biosensors”), and
LifeScan are parties to that certain License Agreement dated April 1, 2002, as
amended on December 7, 2005, and October 25, 2007 (collectively, the “Original
Agreement”), pursuant to which LifeScan granted UBI a license in and to certain
know-how, patents and patent applications relating to electrochemical sensors
acquired by LifeScan from USF Filtration and Separations Group Inc. (“FSG”);
     Whereas, UBS is the operating entity of the Universal Biosensors
organization and the holder of all intellectual property rights of the Universal
Biosensors organization, and UBI’s primary assets are the outstanding shares of
UBS;
     Whereas, UBI desires that UBS be the counter-party to LifeScan under this
Agreement;
     Whereas, UBI, UBS and LifeScan were also parties to that certain
Development and Research Agreement dated April 1, 2002, as amended on March 31,
2004, December 21, 2004, December 7, 2005, June 1, 2007, October 25, 2007, and
May 14, 2009 (collectively, the “D&R Agreement”), pursuant to which LifeScan
granted UBI certain licenses under the “Joint Know-How” and “UNIVERSAL
BIOSENSORS’ Know-How” (as each such term was defined in the D&R Agreement);
     Whereas, LifeScan assigned the D&R Agreement to LifeScan’s Affiliate, Cilag
GmbH International (“Cilag”), on January 1, 2008;
     Whereas, concurrently herewith, UBS and Cilag have entered into an Amended
and Restated Development and Research Agreement dated as of the Restatement Date
(the “Amended and Restated D&R Agreement”);
     Whereas, in order to preserve UBS’s rights and licenses with respect to all
Joint Know-How and Universal Biosensors Know-How (as each such term is defined
herein), developed before LifeScan’s assignment of the D&R Agreement to Cilag,
the parties desire to amend this Agreement to include the grant to UBS of the
licenses with respect to all Joint Know-How and Universal Biosensors Know-How
owned by LifeScan that were originally in the D&R Agreement; and
     Whereas, UBS and LifeScan now desire to amend and restate the Original
Agreement in its entirety on the terms and conditions set forth herein.

1

--------------------------------------------------------------------------------

 

     Now, Therefore, in consideration of the premises and mutual covenants
herein contained, the parties agree to the following:
1. Definitions.
     1.1 “Affiliate” means any entity that directly or indirectly controls, is
controlled by, or is under common control with a party to the Agreement.
“Control” shall mean the possession, direct or indirect, of the power to direct
or cause the direction of the management and policies of the entity, whether
through the ownership of voting securities, by contract or otherwise.
     1.2 “Assignment Date” means January 1, 2008.
     1.3 “Development” means a modification of a component, device, material, or
process.
     1.4 “Effective Date” means April 1, 2002.
     1.5 “Field” means a field-of-use.
     1.6 “First Commercial Sale” means the first transfer of a Product to a
third party for monetary or other consideration; provided, however, that the
transfer of a Product for use in research and development activities (whether or
not for monetary or other consideration) prior to commercial launch of the
Product shall not be considered a “First Commercial Sale.”
     1.7 “Joint Know-How” means all information, technology, and Developments
developed jointly by, or at the joint instruction of, employees or agents of
both, on the one hand, LifeScan or Cilag and, on the other hand, UBS or UBI, in
the course of carrying out the Program, including, without limitation, ideas,
techniques, processes, practices, trade secrets, methods, knowledge, know-how,
skill, expertise, test data and results, analytical and quality control data,
results or descriptions, device, delivery systems, compounds, compositions of
matter and material and all improvements thereto.
     1.8 “Licensed Patents” means those United States patents identified on
Exhibit C attached hereto and made a part hereof, as well as any foreign
counterparts, divisions, continuations, continuations-in-part, renewals,
reissues, re-examinations, and patents issuing therefrom, extensions and
substitutions thereof, and certificates of invention and applications for
certificates of invention with respect to the inventions claimed therein.
     1.9 “LifeScan Acquired Know-How” means all know-how, data, and information
acquired from FSG by LifeScan and related to the LifeScan Acquired Patents.
     1.10 “LifeScan Acquired Patents” means those applications and patents
acquired by LifeScan from FSG and identified on Exhibit A attached hereto and
made a part hereof, as well as any patents issuing therefrom, foreign
counterparts, divisions, continuations, continuations-in-part, renewals,
reissues, re-examinations, and patents issuing therefrom, extensions and
substitutions thereof, and certificates of invention and applications for
certificates of invention with respect to the inventions claimed therein.

2

--------------------------------------------------------------------------------

 

     1.11 “LifeScan Intellectual Property” means any and all intellectual
property and the rights therein including, without limitation, inventions,
ideas, discoveries, trade secrets, know-how, technology, software, designs,
circuit layout rights, concept, data or formulae owned or controlled by
LifeScan.
     1.12 “LifeScan Other Patents” means patent applications and patents
claiming Joint Know-How or Universal Biosensors Know-How that, in each case, was
developed prior to the Assignment Date, excluding any such Joint Know-How or
Universal Biosensors Know-How and patent applications and patents therefor for
which LifeScan either declined the assignment thereof from, or assigned back to,
UBI or UBS.
     1.13 “LifeScan’s Field” means diabetes, including, without limitation:
          (a) the measurement of analytes for purposes of diagnosing, managing,
monitoring, prognosticating, treating, or curing diabetes;
          (b) the collection or analysis of data for the purpose of diabetes
management;
          (c) the delivery of one or more therapeutic agents for the purpose of
treating or managing abnormal glucose metabolism, including, without limitation,
the delivery of insulin, insulin analogs, Glucagon-like proteins/peptides
(“GLPs”), analogs of GLPs or GLP like hormones; and
          (d) the measurement of glucose in humans for any other purpose,
including, without limitation, tight glycemic control.
     1.14 “MESA Patents” means United States Patent Nos. 6,716,577 and
7,498,132, as well as any patents issuing therefrom, foreign counterparts,
divisions, continuations, continuations-in-part, renewals, reissues,
re-examinations, and patents issuing therefrom, extensions and substitutions
thereof, and certificates of invention and applications for certificates of
invention with respect to the inventions claimed therein.
     1.15 “Patent Fees” means filing, prosecution and maintenance fees paid by
LifeScan to third parties (e.g., the USPTO and other patent offices in the
Agreed Jurisdictions (defined in Section 4.1(a)), outside patent counsel, and
third party patent translation service providers) with respect to the LifeScan
Acquired Patents in the Agreed Jurisdictions directed to inventions within the
UBS Fields.
     1.16 “Product” means an article within the UBS Fields that either falls
within the scope of a Valid Claim of one of the LifeScan Acquired Patents or
embodies LifeScan Acquired Know-How.
     1.17 “Program” means research conducted by UBS in LifeScan’s Field jointly
with, or as directed by, LifeScan or Cilag in the course of carrying out UBI’s
responsibilities under Article 2 of the D&R Agreement or UBS’s responsibilities
under Article 2 of the Amended and Restated D&R Agreement.

3

--------------------------------------------------------------------------------

 

     1.18 “Strip Patents” means United States Patent Application Nos. 11/138,080
and 11/284,136, as well as any patents issuing therefrom, foreign counterparts,
divisions, continuations, continuations-in-part, renewals, reissues,
re-examinations, and patents issuing therefrom, extensions and substitutions
thereof, and certificates of invention and applications for certificates of
invention with respect to the inventions claimed therein.
     1.19 “Term” means the period beginning on the Effective Date and, unless
terminated earlier pursuant to Article 5, ending at the end of the term of the
last to expire of the LifeScan Acquired Patents, Licensed Patents, Strip
Patents, and MESA Patents.
     1.20 “UBS Fields” means all Fields outside of LifeScan’s Field.
     1.21 “Universal Biosensors Know-How” means all information, technology, and
Developments developed solely by, or at the sole instruction of, an employee or
agent of UBS or UBI, in the course of carrying out the Program, including,
without limitation, ideas, techniques, processes, practices, trade secrets,
methods, knowledge, know-how, skill, expertise, test data and results,
analytical and quality control data, results or descriptions, devices, delivery
systems, compounds, compositions of matter, and materials and all improvements
thereto.
     1.22 “Valid Claim” means a claim of an issued, unexpired patent that has
not been held invalid by a court of competent jurisdiction or held unpatentable
in a re-examination procedure in the United States Patent and Trademark Office.
2. License.
     2.1 (a) Subject to the provisions of Section 2.2 and Article 3, as of the
Effective Date and for the Term, LifeScan hereby grants to UBS a worldwide,
royalty-free, exclusive license, with the right to sublicense, to make, have
made, use, and sell under and exploit in any way the LifeScan Acquired Patents
and the LifeScan Acquired Know-How in the UBS Fields.
          (b) In order to exercise UBS’s rights to sublicense any or all of the
rights licensed under Section 2.1(a), UBS shall provide that each sublicense
contains the terms and conditions set forth in Article 3 and Section 4.6 of this
Agreement.
     2.2 The license granted in Section 2.1(a) is subject to a reserved
non-exclusive license in LifeScan and its Affiliates to make, have made, use,
and sell under and exploit in any way the LifeScan Acquired Patents and LifeScan
Acquired Know-How in the UBS Fields.
     2.3 In consideration of the license granted in Section 2.1(a), UBS hereby
grants to LifeScan a worldwide, royalty-free, irrevocable, non-exclusive license
to make, have made, use, and sell under and exploit in any way in LifeScan’s
Field any and all intellectual property resulting from UBS’s improvements,
modifications, or adaptations whether or not patentable, in respect of the
LifeScan Acquired Patents, LifeScan Acquired Know-How, or both (collectively,
“Improvements”).
          (a) All right, title and interest in and to the Improvements shall be
in UBS, and UBS at its sole discretion may, if registerable, register any of the
Improvements in such territories (if any) that UBS chooses.

4

--------------------------------------------------------------------------------

 

          (b) UBS shall, at LifeScan’s expense, grant registerable user or
license agreements in respect of any registered intellectual property in any
Improvements that LifeScan determines is required in any particular territory to
make the license in this Section 2.3 effective.
          (c) Registered user or license agreements under Section 2.3(b) shall
be consistent with this Section 2.3, but otherwise shall be in usual or common
form.
     The license granted to LifeScan by UBS in this Section 2.3 shall include
the right to sublicense to LifeScan’s Affiliates.
     2.4 Effective as of October 25, 2007, LifeScan hereby grants to UBS a
worldwide, royalty-free, non-exclusive license, with the right to sublicense, to
make, have made, use, and sell under and exploit in any way the Licensed Patents
in the UBS Fields. The license granted in this Section 2.4 shall last until
expiration of the last to expire of the Licensed Patents. This Section 2.4 shall
survive the expiration or termination of this Agreement.
     2.5 LifeScan hereby grants to UBS a paid-up, non-exclusive license to use
the LifeScan Intellectual Property in LifeScan’s Field only to the extent and
for the period of time necessary that such LifeScan Intellectual Property is
required by UBS to provide one or both of development and supply services to
LifeScan or a LifeScan Affiliate.
     2.6 LifeScan hereby grants to UBS a perpetual, royalty-free, paid-up,
exclusive, worldwide right and license, with the right to sublicense, to make,
have made, use and sell under and otherwise exploit in any way the Joint
Know-How and Universal Biosensors Know-How developed prior to the Assignment
Date, and the LifeScan Other Patents, in each case in the UBS Fields.
     2.7 Effective as of the Restatement Date, LifeScan hereby grants to UBS a
perpetual, royalty-free, paid-up, exclusive, worldwide right and license, with
the right to sublicense, to make, have made, use and sell under and otherwise
exploit in any way the MESA Patents in the UBS Fields.
     2.8 Effective as of the Restatement Date, UBS hereby grants to LifeScan a
perpetual, royalty-free, paid-up, exclusive, worldwide right and license, with
the right to sublicense, to make, have made, use and sell under and otherwise
exploit in any way the Strip Patents in LifeScan’s Field.
     2.9 Promptly after the Restatement Date, and to the extent not previously
transferred to LifeScan, UBS shall transfer to LifeScan all Joint Know-How or
Universal Biosensors Know-How, in each case developed prior to the Assignment
Date, existing as at that date. Such information shall include, without
limitation, copies of all relevant data, drawings, notebooks, and samples.
3. Recapture Rights
     3.1 In order for UBS to maintain the exclusive license granted in
Section 2.1(a), UBS shall use commercially reasonable efforts to use and exploit
the LifeScan Acquired Patents and LifeScan Acquired Know-How in the UBS Fields
directly or through any of UBS’s Affiliates or

5

--------------------------------------------------------------------------------

 

sublicensees; provided, however, that UBS retains the discretion to determine
the means and manner of its exploitation of LifeScan Acquired Patents and
LifeScan Acquired Know-How. For purposes of this Article 3:
          (a) “commercially reasonable efforts” means, with respect to UBS’s
obligation under this Agreement to use and exploit the LifeScan Acquired Patents
and LifeScan Acquired Know-How in the UBS Fields, the level of efforts required
to carry out such obligation in a sustained manner consistent with the efforts
similarly-situated medical diagnostics companies devote to a product of similar
market potential, profit potential or strategic value resulting from their own
research efforts, based on conditions then prevailing;
          (b) “similarly-situated medical diagnostics company” means a company
in the medical diagnostics industry of a size and stage of development (taking
into account, without limitation, market capitalizations, revenues, number of
employees, resources, and manufacturing capabilities) similar to that of UBS;
and
          (c) “exploit” or “exploitation” means:
               (i) using in research and development activities;
               (ii) using in developing, making, selling, and distributing
Products;
               (iii) granting sublicenses in any Field within the UBS Fields;
and
               (iv) developing, in conjunction with Section 3.1(c)(i),
3.1(c)(ii) or 3.1(c)(iii), new patent applications or other intellectual
property that derives from or, is a development of, any of the LifeScan Acquired
Patents and LifeScan Acquired Know-How in the UBS Fields.
     3.2 During the Term, UBS shall provide to LifeScan periodic, written,
summary reports on UBS’s exploitation plans and any Improvements to which
Section 2.3 applies, which reports shall be provided at least one (1) time per
calendar year. LifeScan shall keep confidential any exploitation plans disclosed
to it under this Section 3.2.
     3.3 In the event that LifeScan is approached by a third party that desires
a license in a Field within the UBS Fields in any or all of the LifeScan
Acquired Patents or LifeScan Acquired Know-How, LifeScan shall refer the third
party to UBS by identifying the third party, identifying a contact for the third
party, and providing UBS copies of any correspondence received by LifeScan from
the third party (collectively, a “Referral”). UBS shall acknowledge in writing
to LifeScan receipt of the Referral within 30 days of such receipt.
     3.4 If UBS receives a Referral pursuant to Section 3.3, UBS shall enter
into good faith negotiations for the grant of a license to the third party
unless UBS (directly or through any of its Affiliates or sublicensees):
          (a) is engaged in exploitation of the LifeScan Acquired Patents or
LifeScan Acquired Know-How, as applicable, in the Field that is the subject of
the Referral; or

6

--------------------------------------------------------------------------------

 

          (b) provides to LifeScan evidence that reasonably demonstrates to
LifeScan that UBS has bona fide plans to commence exploitation of the LifeScan
Acquired Patent or LifeScan Acquired Know-How, as applicable, in the Field
within 12 months of the date of UBS’s acknowledgment of the Referral.
     3.5 If UBS fails to enter into negotiations under Section 3.4 within three
(3) months of the date of UBS’s acknowledgment of the Referral, LifeScan shall
have the right to convert the license granted under Section 2.1(a) to a
non-exclusive license with respect to the Field and LifeScan Acquired Patent or
LifeScan Acquired Know-How that is the subject of the Referral.
4. Patent Prosecution and Maintenance; Patent Marking.
     PART A: LifeScan Acquired Patents, Licensed Patents and MESA Patents.
     4.1 (a) LifeScan shall accept liaison and financial responsibility for
prosecution by a patent attorney, in independent practice nominated by LifeScan
and approved by UBS, of the application or applications within the LifeScan
Acquired Patents that, in each case, are directed to inventions within the UBS
Fields to allowance or to the point of necessary appeal from a final rejection
by an Examiner of the USPTO, and those jurisdictions listed on Exhibit B
attached hereto and made a part hereof and any other jurisdiction mutually
agreed upon by the parties (the jurisdictions listed on Exhibit B and such other
mutually agreed jurisdictions, collectively, the “Agreed Jurisdictions”).
          (b) Except as may be later separately agreed upon by the parties in
writing, LifeScan does not accept responsibility for:
               (i) filing or prosecution of any appeal from a final rejection by
an Examiner of the USPTO, or any other jurisdiction, of any of the patent
applications; or
               (ii) the conduct of any interference in which an application or
patent arising from an application may become involved.
     4.2 LifeScan will furnish UBS copies of all office actions and LifeScan’s
proposed responses thereto at least 30 days prior to the earliest date set by
the USPTO or corresponding foreign office for submission of the response and UBS
shall have the right to review and comment on LifeScan’s proposed response to
such action.
     4.3 In the event that LifeScan elects not to proceed with the prosecution
of an application under Section 4.1(a), LifeScan shall notify UBS of such
decision and UBS shall have the right at any time thereafter to assume and
continue at its own expense the prosecution of the application. Upon receipt by
UBS of such notice from LifeScan, LifeScan:
          (a) shall be relieved of all further financial and other
responsibility in respect to the application;
          (b) shall have no further rights thereto in all jurisdictions for
which UBS assumes financial responsibility for the prosecution;

7

--------------------------------------------------------------------------------

 

          (c) shall enter into such assignments or other reasonably necessary
documents in respect thereto in all jurisdictions for which UBS assumes
financial responsibility so as to properly vest ownership and the right to
prosecute the application in UBS or its nominee; and
          (d) shall provide to UBS the file histories of the application in
LifeScan’s possession.
     4.4 Upon issuance of any patents resulting from the applications prosecuted
pursuant to Section 4.1(a), LifeScan will accept responsibility for payment of
maintenance fees for all jurisdictions mutually agreed upon by the parties.
However, LifeScan shall have the right to discontinue the payment of any or all
maintenance fees in any or all countries. In the event LifeScan discontinues
such maintenance payments, LifeScan shall notify UBS of such decision and UBS
may, at its option, maintain the patent solely at its own expense. Upon receipt
by UBS of such notice from LifeScan, LifeScan:
          (a) shall be relieved of all further financial and other
responsibility in respect to the patent at issue;
          (b) shall have no further rights thereto in all jurisdictions for
which UBS has assumed the maintenance payments;
          (c) shall enter into such assignments or other reasonably necessary
documents in respect thereto in all jurisdictions for which UBS assumes
financial responsibility so as to properly vest ownership and the right to
maintain the patent in UBS or its nominee; and
          (d) shall provide to UBS the file histories of the patent in
LifeScan’s possession.
     4.5 (a) In the event that UBS grants a sublicense in the LifeScan Acquired
Patents to a third party (other than in conjunction with the grant to such third
party of a sublicense to exploit within the UBS Fields a Product developed by or
on behalf of UBS or its Affiliate, either alone or in collaboration with such
third party) and receives any lump sum payments (including but not limited to
up-front fees and milestone payments) or actual or minimum royalty payments from
the sublicensee with respect to such sublicense (each, a “Pass-Through
Sublicense Payment”), UBS agrees to pay 50% of such Pass-Through Sublicense
Payment (when received from time to time) to LifeScan in reimbursement of the
Patent Fees paid by LifeScan.
          (b) In the event that there is a First Commercial Sale of a Product by
or on behalf of a third party alone or in conjunction, partnership,
collaboration or the like with UBS or its Affiliate, which Product is developed
by or on behalf of UBS or its Affiliate alone or in collaboration with the third
party, UBS agrees to pay fifty percent (50%) of the Patent Fees paid by LifeScan
prior to the date of the First Commercial Sale (the “Initial Payment”) and fifty
percent (50%) of the Patent Fees incurred by LifeScan thereafter (the “Ongoing
Payment”).
               (i) UBS shall notify LifeScan of the First Commercial Sale date
within 30 days thereof, and LifeScan shall provide to UBS reasonable supporting
documentation of the Patent Fees paid by LifeScan up to the date of the First
Commercial Sale.

8

--------------------------------------------------------------------------------

 

               (ii) UBS shall have the right to elect to make the Initial
Payment either as a lump sum within 45 days of the date of receipt of the
supporting documentation from LifeScan or in equal monthly installment payments
during the 24 calendar months subsequent to the date of receipt of the
supporting documentation.
               (iii) LifeScan shall invoice UBS on an annual basis for the
Ongoing Payment and provide reasonable supporting documentation therefor, and
payment of each such invoice shall be made within 45 days of receipt by UBS from
LifeScan of the invoice and supporting documentation.
          (c) UBS shall not structure any third party transaction contemplated
by Section 4.5(a) or (b) in a manner such that the purpose of such structure is
to circumvent or minimize its obligation to make payments that would otherwise
be owed to LifeScan under this Agreement.
          (d) In no event shall UBS be obligated to pay, nor shall LifeScan be
entitled to receive from UBS, cumulative amounts under Sections 4.5(a) and
4.5(b) in excess of 50% of the cumulative Patent Fees paid by LifeScan.
               (i) UBS’s payment obligations to LifeScan under Section 4.5(a)
shall cease at the end of the term of the LifeScan Acquired Patents that are the
subject of the Pass-Through Sublicense Payment from the sublicensee.
               (ii) UBS’s payment obligations to LifeScan under Section 4.5(b)
shall cease at the end of the term of the LifeScan Acquired Patents within the
claims of which the Product falls.
          (e) LifeScan acknowledges to UBS that, apart from the rights to
payments under Sections 4.5(a) and 4.5(b), LifeScan is not entitled to receive
any other amount by way of royalty or similar payment in respect of the license
granted herein.
     4.6 UBS agrees to place in a conspicuous location on products sold to third
parties a patent notice, in accordance with 35 U.S.C. §287, and any
corresponding provision of the laws of a jurisdiction other than the United
States in which a Product is being sold, identifying the relevant LifeScan
Acquired Patents, Licensed Patents, LifeScan Other Patents, or MESA Patents, if
any.
PART B: LifeScan Other Patents
     4.7 (a) LifeScan will, at LifeScan’s sole discretion, accept liaison and
financial responsibility for:
               (i) preparation, by a patent attorney in independent practice
nominated by LifeScan and approved by UBS, of LifeScan Other Patents;
               (ii) filing upon execution by the inventors of such application
or applications within the LifeScan Other Patents at least in the Agreed
Jurisdictions, provided that

9

--------------------------------------------------------------------------------

 

UBS may elect, at its own expense, to file the application or applications in
additional countries; and
               (iii) prosecution by the attorney of such application or
applications to allowance or to the point of necessary appeal from a final
rejection by an examiner in the Agreed Jurisdictions.
          (b) Except as may be later separately agreed upon by the parties in
writing, LifeScan does not accept responsibility for:
               (i) filing or prosecution of any appeal from a final rejection by
and examiner in any of the Agreed Jurisdictions of any patent application within
the LifeScan Other Patents; or
               (ii) the conduct of any interference in which an application or
applications within the LifeScan Other Patents may become involved.
          (c) LifeScan will furnish UBS copies of:
               (i) any applications filed pursuant to Section 4.7(a)(i);
               (ii) any substantive office actions received from any of the
Jurisdictions, pertaining to the applications filed pursuant to
Section 4.7(a)(ii); and
               (iii) any substantive responses to office actions filed pursuant
to Section 4.7(a)(iii).
          (d) UBS shall assist, as is deemed necessary by LifeScan, in
preparing, filing, and prosecuting the applications filed pursuant to this
Section 4.7 and maintaining and defending the patents issuing therefrom. During
the Term, such assistance shall be at no cost to LifeScan or its Affiliates
except for the costs of travel and accommodations for travel requested by
LifeScan or its Affiliates. After expiration or termination of the Agreement,
such assistance shall be at LifeScan’s cost.
          (e) In the event that LifeScan elects not to proceed with the filing
or prosecution of any application under this Section 4.7, respectively, UBS
shall have the right at any time thereafter and by written notice to LifeScan to
assume and continue at its own expense filing, prosecution, or both of the
application. Upon receipt by LifeScan of such notice, LifeScan:
               (i) shall be relieved of all further financial and other
responsibility in respect to the application;
               (ii) shall have no further rights thereto in all countries for
which UBS has assumed the payments;
               (iii) shall enter into such assignments or other reasonably
necessary documents in respect thereto in all countries for which UBS assumes
financial responsibility so

10

--------------------------------------------------------------------------------

 

as to properly vest ownership and the right to prosecute the application in UBS
or its nominee; and
               (iv) shall provide to UBS the file histories of the application
in LifeScan’s possession.
          (f) Upon issuance of any patents resulting from applications filed
pursuant to Section 4.7(a)(ii), LifeScan will accept responsibility for payment
of maintenance fees for the Agreed Jurisdictions and all other countries elected
by LifeScan. However, LifeScan shall have the right at any time to discontinue
the payment of any or all maintenance fees in any or all such countries. In the
event LifeScan discontinues such maintenance payments, UBS may, at its option
and by written notice to LifeScan, maintain the patent at its own expense and
license it to third parties. Upon receipt by LifeScan of such notice, LifeScan:
               (i) shall be relieved of all further financial and other
responsibility in respect to the patent at issue;
               (ii) shall have no further rights thereto in all countries for
which UBS has assumed the payments;
               (iii) shall enter into such assignments or other reasonably
necessary documents in respect thereto in all countries for which UBS assumes
financial responsibility so as to properly vest ownership and the right to
maintain the patent in UBS or its nominee; and
               (iv) shall provide to UBS the file histories of the patent in
LifeScan’s possession.
5. Termination.
     5.1 This Agreement shall extend until the end of the Term unless terminated
earlier in accordance with this Article 5.
     5.2 This Agreement may be terminated by LifeScan in the event that UBS
fails to use commercially reasonable efforts to exploit the LifeScan Acquired
Patents and LifeScan Acquired Know-How. For purposes of this Section 5.2:
          (a) “commercially reasonable efforts” and “exploit” have the same
meaning as in Section 3.1; and
          (b) if LifeScan wishes to terminate the Agreement pursuant to this
Section 5.2, LifeScan shall first provide UBS with 90 days’ written notice of
its intent to so terminate and, if at the expiration of the 90 days, UBS has not
provided evidence to LifeScan that UBS is using commercially reasonable efforts
to exploit the LifeScan Acquired Patents and the LifeScan Acquired Know-How,
this Agreement shall terminate on the 91st day.
     5.3 This Agreement may be terminated by LifeScan in the event that UBS is
liquidated or is wound up or is in persistent and material breach of its
obligations under this Agreement. LifeScan shall first provide UBS with 90 days’
written notice of its intent to so

11

--------------------------------------------------------------------------------

 

terminate and, if at the expiration of the 90 days, UBS has not rectified the
breach, this Agreement shall terminate on the 91st day.
     5.4 In the event that LifeScan terminates this Agreement pursuant to
Section 5.2 or Section 5.3, any sublicense previously granted by UBS to a third
party under the Acquired LifeScan Patents, Acquired LifeScan Know-How or both
that is in effect immediately prior to such termination shall survive such
termination as a direct license from LifeScan to such sublicensee on the terms
and conditions set forth in this Agreement, provided that the sublicensee:
(a) is not in material breach of any provision of this Agreement; and (b) agrees
to be bound to LifeScan as a licensor under the terms and conditions of this
Agreement, except that the sublicensee’s obligation under Section 3.1 shall be
limited to the Field(s) within the UBS Fields in which UBS granted such
sublicensee a sublicense under the Acquired LifeScan Patents, Acquired LifeScan
Know-How or both.
     5.5 The provisions of this Agreement that by their terms are meant to
survive termination or expiration, including Sections 2.4, 2.5 (solely to the
extent that UBS has any continuing obligation under a separate agreement to
provide one or both of development and supply services to LifeScan or a LifeScan
Affiliate), 2.6, 2.7, 2.8, 5.4 and 5.5 and Articles 7, 8, 9 and 10, shall
survive termination or expiration of the Agreement.
6. Enforcement of Patents.
PART A: LifeScan Acquired Patents and MESA Patents.
     6.1 (a) In the event that UBS becomes aware of any actual or alleged
unlicensed infringement of a LifeScan Acquired Patent or MESA Patent within one
of the UBS Fields, UBS shall bring such infringement to LifeScan’s attention in
writing (such writing, a “LifeScan Patent Infringement Notice”), and LifeScan
shall have the first right, but not the obligation, to:
               (i) secure cessation of the infringement;
               (ii) enter suit against the infringer; or
               (iii) engage, along with UBS, in bona fide negotiations for the
acceptance by the infringer of a sublicense under the patents on terms mutually
agreeable to LifeScan and UBS.
Any recovery realized by LifeScan as a result of any litigation, other
enforcement activity or execution of a sublicense within any UBS Fields as
described in this Section 6.1(a) (whether by way of damages, profits, awards,
settlement or otherwise) shall be first allocated to reimbursement of
unreimbursed external legal fees and expenses incurred by LifeScan, and then
toward reimbursement of any of unreimbursed external legal fees and expenses of
UBS, and then the remainder shall be shared by the parties, with LifeScan
retaining fifty percent (50%) of such remainder and paying to UBS fifty percent
(50%) of such remainder.
          (b) If, within six (6) months of receipt of a LifeScan Patent
Infringement Notice, LifeScan has not secured cessation of the infringement or
entered suit against the infringer, and LifeScan, UBS and the infringer have not
entered into a sublicense, then UBS shall

12

--------------------------------------------------------------------------------

 

thereafter have the right to sue for the infringement at its own expense, and
any recovery realized by UBS as a result thereof (whether by way of damages,
profits, awards, settlement or otherwise) shall first be allocated to
reimbursement of unreimbursed external legal fees and expenses incurred by UBS,
and then toward reimbursement of any of unreimbursed external legal fees and
expenses of LifeScan, and then the remainder shall be shared by the parties,
with UBS retaining fifty percent (50%) of such remainder and paying to LifeScan
fifty percent (50%) of such remainder.
          (c) In the event a party brings an infringement action in accordance
with this Section 6.1:
               (i) the other parties shall cooperate fully, including, if
required to bring such action, the furnishing of a power of attorney or being
named as a party;
               (ii) neither party shall have the right to settle any patent
infringement litigation under this Section 6.1 with respect to infringement of a
LifeScan Acquired Patent or MESA Patent within the UBS Fields without the prior
written consent of the other party, which shall not be unreasonably withheld or
delayed; and
               (iii) the party bringing the infringement action shall incur no
liability to the other party as a consequence of such litigation or any
unfavorable decision resulting therefrom including any decision holding the
patent invalid or unenforceable.
     6.2 Nothing in this Agreement shall be construed as an obligation on
LifeScan’s part to enforce or defend the LifeScan Acquired Patents, or MESA
Patents.
PART B: Strip Patents.
     6.3 (a) In the event that LifeScan becomes aware of any actual or alleged
unlicensed infringement of a Strip Patent within LifeScan’s Field, LifeScan
shall bring such infringement to UBS’s attention in writing (such writing, a
“Strip Patent Infringement Notice”) and UBS shall have the first right, but not
the obligation to:
               (i) secure cessation of the infringement;
               (ii) enter suit against the infringer; or
               (iii) engage, along with LifeScan, in bona fide negotiations for
the acceptance by the infringer of a sublicense under the patents on terms
mutually agreeable to LifeScan and UBS.
Any recovery realized by UBS as a result of any litigation, other enforcement
activity or execution of a sublicense within LifeScan’s Field as described in
this Section 6.3(a) (whether by way of damages, profits, awards, settlement or
otherwise) shall be first allocated to reimbursement of unreimbursed external
legal fees and expenses incurred by UBS, and then toward reimbursement of any of
unreimbursed external legal fees and expenses of LifeScan, and then the
remainder shall be shared by the parties, with UBS retaining fifty percent (50%)
of such remainder and paying to LifeScan fifty percent (50%) of such remainder.

13

--------------------------------------------------------------------------------

 

          (b) If, within six (6) months of receipt of a Strip Patent
Infringement Notice, UBS has not secured cessation of the infringement or
entered suit against the infringer, and LifeScan, UBS and the infringer have not
entered into a sublicense, then LifeScan shall thereafter have the right to sue
for the infringement at its own expense, and any recovery realized by LifeScan
as a result thereof (whether by way of damages, profits, awards, settlement or
otherwise) shall first be allocated to reimbursement of unreimbursed external
legal fees and expenses incurred by LifeScan, and then toward reimbursement of
any of unreimbursed external legal fees and expenses of UBS, and then the
remainder shall be shared by the parties, with LifeScan retaining fifty percent
(50%) of such remainder and paying to UBS fifty percent (50%) of such remainder.
          (c) In the event a party brings an infringement action in accordance
with this Section 6.3:
               (i) the other parties shall cooperate fully, including, if
required to bring such action, the furnishing of a power of attorney or being
named as a party;
               (ii) neither party shall have the right to settle any patent
infringement litigation under this Section 6.3 with respect to infringement of a
Strip Patent within LifeScan’s Field without the prior written consent of the
other party, which shall not be unreasonably withheld or delayed; and
               (iii) the party bringing the infringement action shall incur no
liability to the other party as a consequence of such litigation or any
unfavorable decision resulting therefrom including any decision holding the
patent invalid or unenforceable.
     6.4 Nothing in this Agreement shall be construed as an obligation on UBS’s
part to enforce or defend the Strip Patents.
PART C: LifeScan Other Patents
     6.5 UBS and LifeScan shall each give prompt notice to one another of any
infringement by third parties of the Joint Know-How or Universal Biosensors
Know-How, in each case developed prior to the Assignment Date, or LifeScan Other
Patents licensed hereunder as may come to its respective knowledge. UBS shall
have the right, but not the obligation, to pursue legal action against
infringement of such Joint Know-How, Universal Biosensors Know-How or LifeScan
Other Patents, in the UBS Fields by third parties, including defending any
declaratory judgment action. LifeScan shall cooperate with UBS and provide such
non-monetary assistance as UBS may reasonably request in connection with such
action. LifeScan shall have the right to participate in and be represented by
independent counsel in such action at its own expense. Any recovery realized by
UBS as a result of any litigation, other enforcement activity or execution of a
sublicense (whether by way of damages, profits, awards, settlement or otherwise)
shall be first allocated to reimbursement of unreimbursed external legal fees
and expenses incurred by UBS and then toward reimbursement of unreimbursed
external legal fees and expenses of LifeScan. UBS shall incur no liability to
LifeScan as a consequence of such litigation or any resulting unfavorable
decision including any decision holding any LifeScan Other Patent invalid or
unenforceable.

14

--------------------------------------------------------------------------------

 

7. Warranties
     7.1 UBS represents and warrants that: (a) it is the sole owner of all
intellectual property rights of UBS and its Affiliates; (b) that it is the sole
owner of the Strip Patents; and (c) it has assigned all right, title and
interest in and to the LifeScan Other Patents to LifeScan. LifeScan represents
and warrants that it is the sole owner of the LifeScan Acquired Patents,
Licensed Patents, MESA Patents and LifeScan Other Patents. In addition, each
party warrants that it has the ability to enter into this Agreement, that to the
best of their knowledge there are no outstanding written or oral agreements to
which such party is a party that are inconsistent with the Agreement, and that
it will not, while the Agreement is in force, enter into any written or oral
agreement in conflict with the Agreement.
     7.2 Nothing in this Agreement shall be construed as: (a) a warranty or
representation by LifeScan of the validity, enforceability, or scope of the
LifeScan Acquired Patents, Licensed Patents, MESA Patents or LifeScan Other
Patents; or (b) a warranty or representation by UBS of the validity,
enforceability, or scope of the Strip Patents.
     7.3 Nothing in this Agreement shall be construed as: (a) a warranty or
representation by LifeScan that a Product, or a product that falls within the
scope of a claim of one of the LifeScan Acquired Patents, MESA Patents, Licensed
Patents or LifeScan Other Patents, that, in each case, is made, used, or sold by
UBS, its Affiliates or its sublicensees under the licenses granted to UBS herein
is or will be free from infringement of the intellectual property of third
parties; or (b) a warranty or representation by UBS that a product that falls
within the scope of a claim of one of the Strip Patents and is made, used, or
sold by LifeScan, its Affiliates or sublicensees under the license granted to
LifeScan herein is or will be free from infringement of the intellectual
property of third parties. LifeScan shall not be responsible for any award of
damages arising out of charges that UBS, alone or in combination with other
entities or persons, infringed or infringes any claim of any third party patent
by making, having made, using, selling or otherwise distributing Products, or
other products that falls within the scope of a claim of one of the LifeScan
Acquired Patents, MESA Patents, Licensed Patents or LifeScan Other Patents. UBS
shall not be responsible for any award of damages arising out of charges that
LifeScan, alone or in combination with other entities or persons, infringed or
infringes any claim of any third party patent by making, having made, using,
selling or otherwise distributing a product that falls within the scope of a
claim of one of the Strip Patents.
     Except as expressly set forth in Section 7.1, LIFESCAN MAKES NO WARRANTIES
OF ANY NATURE WITH RESPECT TO THE LIFESCAN ACQUIRED PATENTS, LICENSED PATENTS,
MESA PATENTS, LIFESCAN OTHER PATENTS AND LIFESCAN ACQUIRED KNOW-HOW, INCLUDING,
WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR PARTICULAR
PURPOSE, OR OTHERWISE. Except as expressly set forth in Section 7.1, UBS MAKES
NO WARRANTIES OF ANY NATURE WITH RESPECT TO THE STRIP PATENTS, INCLUDING,
WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR PARTICULAR
PURPOSE, OR OTHERWISE.

15

--------------------------------------------------------------------------------

 

8. Notices
     All notices, reports, requests, or statements provided for in this
Agreement shall be given in writing and may be served either by personal
delivery or by depositing the same, postage prepaid, in the United States first
class, certified, or registered mails (date of deposit will be considered date
of delivery) addressed to the parties respectively at the following addresses:
(a) In the case of UBS:
Chief Executive Officer
Universal Biosensors Pty Ltd
1 Corporate Avenue
Rowville, Victoria 3178
Australia
Fax: +613 9213 9099
With a copy to:
Chief Financial Officer
Universal Biosensors Pty Ltd
1 Corporate Avenue
Rowville, Victoria 3178
Australia
Fax: +613 9213 9099
And a copy to:
Beth Hughes
Venable Attorneys at Law
8010 Towers Crescent Drive
Suite 300
Vienna, Virginia 22182
USA
Fax: +1 (703) 821-8949
(b) In the case of LifeScan:
LifeScan, Inc.
1000 Gibraltar Drive
Milpitas, California 95035
Attn: President
Fax: +1 (408) 956-4701

16

--------------------------------------------------------------------------------

 

With a copy to:
Chief Patent Counsel
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933 U.S.A.
Fax: +1 732-524-5008
9. Arbitration
     Any controversy or claim arising out of or relating to this Agreement or
the validity, inducement, or breach thereof, shall be settled by arbitration
before a single arbitrator in accordance with the Commercial Arbitration Rules
of the American Arbitration Association (“AAA”) then pertaining (available at
www.adr.org), except where those rules conflict with this provision, in which
case this provision controls. Any court with jurisdiction shall enforce this
clause and enter judgment on any award. The arbitrator shall be an attorney who
has at least 15 years of experience with a law firm or corporate law department
of over 25 lawyers or who was a judge of a court of general jurisdiction. The
arbitrator shall be selected within ten days of commencement of the arbitration
from the AAA’s National Roster of Arbitrators pursuant to agreement or through
selection procedures administered by the AAA. The arbitration shall be held in
San Francisco, California and in rendering the award the arbitrator must apply
the substantive law of New York (except where that law conflicts with this
clause), except that the interpretation and enforcement of this arbitration
provision shall be governed by the Federal Arbitration Act. Within 45 days of
initiation of arbitration, the parties shall reach agreement upon and thereafter
follow procedures assuring that the arbitration will be concluded and the award
rendered within no more than eight months from selection of the arbitrator.
Failing such agreement, the AAA will design and the parties will follow
procedures that meet such a time schedule. Each party has the right before or,
if the arbitrator cannot hear the matter within an acceptable period, during the
arbitration to seek and obtain from the appropriate court provisional remedies
such as attachment, preliminary injunction, replevin, etc., to avoid irreparable
harm, maintain the status quo or preserve the subject matter of the arbitration.
THE ARBITRATOR SHALL NOT AWARD ANY PARTY PUNITIVE, EXEMPLARY, MULTIPLIED OR
CONSEQUENTIAL DAMAGES, AND EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT TO
SEEK SUCH DAMAGES. NO PARTY MAY SEEK OR OBTAIN PREJUDGMENT INTEREST OR
ATTORNEYS’ FEES OR COSTS.
10. General Provisions.
     10.1 This Agreement, or any of its rights and obligations, shall not be
assigned or transferred in whole or in part by either party without the prior
written consent of the other party.
          (a) Any attempted assignment or transfer of such rights or obligations
without consent shall be void.
          (b) A party shall not unreasonably withhold its consent to an
assignment or transfer as part of the sale of the whole or part of the business
of the assignor or transferor if the assignee or transferee is of reasonable
financial standing.

17

--------------------------------------------------------------------------------

 

     10.2 This Agreement shall be binding upon and inure to the benefit of the
parties and their respective successors and assigns.
     10.3 The waiver of either party, whether express or implied, of any
provision of this Agreement, or of any breach or default of either party, shall
not be construed to be a continuing waiver of such provision, or any succeeding
breach or default or of a waiver of any other provision of this Agreement.
     10.4 The interpretation, validity, and performance of this Agreement shall
be governed by the laws of the State of New York, except for such laws directing
application of the laws of another jurisdiction.
     10.5 Each party shall comply with all applicable United States and foreign
governmental laws and regulations including, without limitation, any such laws
directed to importation and exportation.
     10.6 It is the mutual desire and intent of LifeScan and UBS to provide
certainty as to their future rights and remedies against each other by defining
the extent of their mutual undertaking as provided herein. Both LifeScan and UBS
acknowledge and agree: (a) that no representation or promise not expressly
contained in this Agreement has been made by the other party hereto or by any of
its agents, employees, representatives or attorneys; (b) that such Agreement is
not being entered into on the basis of, or in reliance on, any promise or
representation, expressed or implied, covering the subject matter hereof, other
than those which are set forth expressly in this Agreement; and (c) that each
party has had the opportunity to be represented by counsel of its own choice in
this matter, including the negotiations which preceded the execution of this
Agreement.
     10.7 This Agreement represents the entire understanding between UBS and
LifeScan with respect to the subject matter in this Agreement, and supersedes
any and all implied or express understandings, agreements or obligations between
the parties with respect thereto whether written or oral, including, without
limitation, the Original Agreement.
[Signature page follows]

18

--------------------------------------------------------------------------------

 

     In Witness Whereof, the parties hereto have duly executed this Agreement as
of the Restatement Date.

              Universal Biosensors Pty Ltd        
 
           
By:
/s/ Paul Wright
 
  By: /s/ Salesh Balak
 
 
Name:  Paul Wright
 
  Name:  Salesh Balak
 

Title:  CEO
 
    Title:  CFO
 
Date: 
8/29/11
 
  Date:  8/29/11
 
 
           
LifeScan, Inc.
     
 
           
By:
/s/ John Carlson
 
       

Name:  John Carlson
 
       

Title:  Worldwide VP R&D.
 
       
Date: 
8/25/11
 
       

Universal Biosensors, Inc. hereby acknowledges and agrees that this Agreement
supersedes the Original Agreement in its entirety.

             
Universal Biosensors, Inc.
     
 
           
By:
/s/ Paul Wright
 
       

Name:  Paul Wright
 
       
 
Title:  CEO
 
       
Date: 
8/29/11
 
       

19

--------------------------------------------------------------------------------

 

EXHIBIT A
LifeScan Acquired Patents

              Current Docket No.   Title   Pat./Appln. No.   Filing/issue Date
*LFS0196USA
  Electrochemical Cells   US 5,863,400   01/26/1999
 
           
*LFS0197USA
  Method of Defining an Electrode Area   US 5,980,709   11/09/1999
 
           
LFS0198US
  Electrochemical Cell   US 6,284,125   09/04/2001
 
           
LFS0198CNT3
  Electrochemical Cell   US 7,608,175   10/27/2009
 
           
LFS0198USCNT4
  Electrochemical Cell   US 7,604,722   10/20/2009
 
           
LFS0198USCNT5
  Electrochemical Cell   USSN 12/560,773   09/16/2009
 
           
LFS0198USCNT6
  Electrochemical Cell   USSN 12/560,780   09/16/2009
 
           
LFS0198USCNT7
  Electrochemical Cell   USSN 12/567,433   09/25/2009
 
           
LFS0199USA
  Electrochemical Cell   US 6,179,979   01/30/2009
 
           
LFS0199USCNT1
  Electrochemical Cell   US 7,431,814   10/07/2008
 
           
LFS0199USCNT2
  Electrochemical Cell   USSN 11/487,728   07/17/2006
 
           
LFS0199USRE1
  Electrochemical Cell   USSN 12/899,342   10/06/2010
 
           
LFS0200USA
  Electrochemical Method   US 5,942,102   08/24/1999
 
           
*LFS0201US
  Analytic Cell   US 6,193,865   02/27/2001
 
           
*LFS0202USA
  Electrochemical Cell   US 6,454,921   09/24/2002
 
           
LFS0203USA
  Sensor Connector Means   US 6,379,513   04/30/2002
 
           
LFS0203USCNT2
  Sensor Connector Means   USSN 11/434,442   05/15/2006
 
           
*LFS0204US
  Method and Apparatus for Automatic Analysis   US 6,325,917   12/04/2001
 
           
*LFS0205US
  Heated Electrochemical Cell   US 6,475,360   11/05/2002
 
           
*LFS0206USA
  Sensor With Improved Shelf Life   US 6,652,734   11/25/2003
 
           
*LFS0206USACON
  Sensor With Improved Shelf Life   US 7,335,292   02/26/2008
 
           
*LFS0206USCON2
  Sensor With Improved Shelf Life   USSN 11/926,369   10/29/2007

 

*   Asterisk indicates cases no longer prosecuted or maintained by J&J, for
which UBS declined to assume responsibility, and that will become abandoned in
due course.

A-1

--------------------------------------------------------------------------------

 

EXHIBIT A

              Current Docket No.   Title   Pat./Appln. No.   Filing/issue Date
LFS0207US
  Electrochemical Cell   US 6,174,420   01/16/2001
 
           
*LFS0208USNP
  Method of Preventing Short Sampling of a Capillary or Wicking Fill Device   US
6,571,651   06/02/2003
 
           
*LFS0208USDIV1
  Method of Preventing Short Sampling of a Capillary or Wicking Fill Device   US
7,043,821   05/16/2006
 
           
*LFS0208USDIV
  Method of Preventing Short Sampling of a Capillary or Wicking Fill Device   US
7,131,342   11/07/2006
 
           
*LFS0210USA
  Method of Filling an Amperometric Cell   US 6,592,744   07/15/2003
 
           
*LFS0210USACON
  Method of Filling an Amperometric Cell   US 7,041,210   05/09/2006
 
           
*LFS0211US
  Method and Device for Sampling and Analyzing Interstitial Fluid in Whole Blood
Samples   US 6,612,111   09/02/2003
 
           
LFS0211USCNT2
  Method and Device for Sampling and Analyzing Interstitial Fluid in Whole Blood
Samples   USSN 10/830,841   04/22/04
 
           
*LFS0213USA
  Antioxidant Sensor   US 6,638,415   10/28/2003
 
           
LFS0215USA
  Electrochemical
Method for Measuring
Chemical Reaction Rates   US 6,444,115   09/03/2002
 
           
LFS0216USA
  Hemoglobin Sensor   US 6,632,349   10/14/2003
 
           
LFS0217USA
  Electrochemical Cell   US 6,413,410   07/02/2002
 
           
LFS0218USA
  Electrochemical Cell   US 6,521,110   02/18/2003
 
           
LFS0219
  Electrochemical Cell   US 6,863,801   03/08/2005
 
           
LFS0220USAPCT
  Electrochemical Cell   US 7,431,820   10/07/2008
 
           

 

*   Asterisk indicates cases no longer prosecuted or maintained by J&J, for
which UBS declined to assume responsibility, and that will become abandoned in
due course.

A-2

--------------------------------------------------------------------------------

 

EXHIBIT A

              Current Docket
No.   Title   Pat./Appln. No.   Filing/issue Date
LFS0220USCNT1
  Electrochemical Cell   USSN 12/196,704   08/22/2008
 
           
*LFS221USA
  Method and Apparatus for Automatic Analysis   US 6,852,212   02/08/2005
 
           
LFS222USCNT1
  Electrochemical Cell Connector   US 7,846,312   12/07/2010
 
           
LFS222USNP
  Method of Forming an Electrical Connection Between an Electrochemical Cell and
Meter   US 6,946,067   09/20/2005
 
           
LFS223USACNT
  Electrochemical Cell   US 6,960,289   11/01/2005
 
           
LFS223USACNT2
  Sensor Connector Means   USSN 11/434,442   05/15/2006
 
           
LFS224USCNT
  Sensor Connector Means   US 7,045,046   05/16/2006
 
           
*LFS228USA
  Heated Electrochemical Cell   US 6,878,251   04/12/2005
 
           
*LFS252USACNT
  Method and Device for Sampling and Analyzing Interstitial Fluid and Whole
Blood Samples   US 6,939,312   09/06/2005
 
           
LFS253USCNT
  Electrochemical Method for
Measuring Chemical Reaction Rates   US 7,022,217   04/04/20006
 
           

 

*   Asterisk indicates cases no longer prosecuted or maintained by J&J, for
which UBS declined to assume responsibility, and that will become abandoned in
due course.

A-3

--------------------------------------------------------------------------------

 

EXHIBIT B
Patent Filing Jurisdictions
Australia
Canada
EPO:
France
Germany
Italy
Netherlands
Spain
United Kingdom
Japan
United States

 

--------------------------------------------------------------------------------

 

EXHIBIT C
Licensed Patents

          Patent Number   Issued Date   Title
US 6,872,298
  March 29, 2005   Determination of Sample Volume Adequacy in Biosensor Devices
 
       
US 6,797,150
  September 28, 2004   Determination of Sample Volume Adequacy in Biosensor
Devices
 
       
US 7,195,704
  March 27, 2007   Determination of Sample Volume Adequacy in Biosensor Devices
 
       
US 6,193,873
  February 27, 2001   Sample Detection to Initiate Timing of an Electrochemical
Assay
 
       
US 6,676,995
  January 13, 2004   Solution Striping System
 
       
US 6,689,411
  February 10, 2004   Solution Striping System